Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory...
42 insider purchases on record · latest filing 2025-06-23.
Insiders have also filed 24 sale transactions at MBRX.